Stone J H, Tun W, Hellman D B
Division of Rheumatology, The Johns Hopkins Hospital, Baltimore, Maryland, USA.
J Rheumatol. 1999 May;26(5):1134-9.
To examine our experience with methotrexate (MTX) and daily prednisone (PRED) as the initial treatment of Wegener's granulomatosis (WG).
Between November 1992 and November 1997, we treated 19 patients with non-life threatening WG with the combination of oral weekly MTX (starting at 7.5-10.0 mg/week) and daily PRED (median starting dose 40 mg/day, range 20-60). The MTX dose was increased to 15 mg/week by the end of the first month, and then by 2.5 mg/week until the disease was controlled. We attempted to taper PRED to 20 mg/day by the end of the second month, but did not use alternate day corticosteroids. Before treatment with this regimen, no patient had received previous treatment for WG.
At presentation, the average number of organ systems involved was 3.6. Nine of the 19 patients (47%) had glomerulonephritis, but none had a serum creatinine > 1.2 mg/dl at presentation. Only 37% of the patients were hospitalized at presentation. Seventeen of 19 patients (89%) improved with treatment, and 14 (74%) achieved remission. However, half those who achieved remission suffered relapses, and no patient achieved a durable, complete remission (disease-free status free of all medications). Fifteen patients (79%) were able to taper PRED to < 10 mg/day. Seven of 8 disease relapses responded to increases of MTX and/or PRED. Only one patient developed glomerulonephritis while receiving treatment and required a change of therapy to cyclophosphamide. There were no deaths among patients in this series. Treatment with MTX and PRED was well tolerated: only 2 (11%) of the patients stopped treatment because of side effects (major liver function test abnormalities in both cases). No patient suffered permanent morbidity from MTX treatment.
In selected patients with WG, the combination of MTX and daily PRED effectively controls the disease. However, chronic disease courses are the rule with this treatment regimen, and the likelihood of disease relapse is high. In our experience, the use of MTX and PRED in WG was safer than previously described, despite the use of daily corticosteroids.
探讨甲氨蝶呤(MTX)与每日服用泼尼松(PRED)联合用于韦格纳肉芽肿(WG)初始治疗的经验。
1992年11月至1997年11月期间,我们对19例无生命威胁的WG患者采用口服每周一次MTX(起始剂量7.5 - 10.0毫克/周)与每日服用PRED(起始中位剂量40毫克/天,范围20 - 60毫克/天)联合治疗。MTX剂量在第一个月末增至15毫克/周,然后每周增加2.5毫克,直至疾病得到控制。我们试图在第二个月末将PRED减至20毫克/天,但未使用隔日服用的皮质类固醇。在采用该方案治疗前,所有患者均未接受过WG的先前治疗。
就诊时,平均累及的器官系统数量为3.6个。19例患者中有9例(47%)患有肾小球肾炎,但就诊时血清肌酐均未>1.2毫克/分升。就诊时仅37%的患者住院。19例患者中有17例(89%)治疗后病情改善,14例(74%)实现缓解。然而,实现缓解的患者中有一半复发,且无患者实现持久的完全缓解(无需所有药物的无病状态)。15例患者(79%)能够将PRED减至<10毫克/天。8次疾病复发中有7次对MTX和/或PRED剂量增加有反应。仅1例患者在接受治疗时发生肾小球肾炎,需要更换为环磷酰胺治疗。该系列患者中无死亡病例。MTX和PRED治疗耐受性良好:仅2例(11%)患者因副作用停止治疗(两例均为主要肝功能检查异常)。无患者因MTX治疗出现永久性疾病。
对于部分WG患者,MTX与每日服用PRED联合可有效控制疾病。然而,采用该治疗方案慢性病程常见,疾病复发可能性高。根据我们的经验,尽管使用了每日服用的皮质类固醇,但在WG中使用MTX和PRED比先前描述的更安全。